COSINR

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Feb 13, 2018 → Nov 28, 2025

Cited window

Jun 14, 2018 → Nov 28, 2025

Retrieved

Oct 30, 2026

Title

A Randomized Phase I Trial to Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (COSINR Study)

Registry

NCT03223155

Study IDs

IRB17-0547

Sponsor

University of Chicago

Design

Phase 1 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

78 actual

Registered

2017-07-21

Start

2017-09-07 actual

Primary completion

2026-12 estimated

Primary endpoint

Number of serious adverse events

Interventions

3 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –118 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition do not represent all HCPs or all public discussion; repeated posts and reposts are not independent clinical opinions.
• –Some discussion passages and treatment-development suggestions were not fully assessed, and unnamed references or alternative transcriptions may be missing. Absence of a view here does not establish that no such view exists or that every proposed approach has been characterized.
• –A complete protocol and the complete main clinical-results publication are not available. Presentation summaries and participant recalculations should not substitute for a full endpoint-level assessment.
• –The registry condition labels describe small cell lung cancer, while the trial title, methods statement and commentary specify stage IV NSCLC. The report follows the latter clinical setting.
• –Clinical associations involving AREG or YTHDF2 do not establish causation, predictive utility, a sequencing rule or benefit from a targeted intervention.
• –Some numerical presentation summaries omit denominators, timepoints or group assignments; values from different presentations are not interchangeable.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –A speaker's favorable appraisal accompanies a post sharing COSINR results. Another speaker's AREG explanations concern the group's own research, including COSINR analyses. These should not be read as independent external reception.
• –A speaker's involvement is described by the source as working for The University, the trial's sponsor; this description is not independent verification of employment or a reason to weight the view as external consensus.
• –Surgical, bladder-RT and other-trial examples are used only where they qualify the connected treatment or evidence question; they are not COSINR treatment arms or outcomes. The pulmonary-vessel-ligation comparison is a reported study observation posted in 2019 about lung-cancer resection.
• –Concerns about patient fear, specialty bias and media effects are attributed opinions or anticipated risks, not independently measured findings.

How reports are built and checked: Methods.

Last checked for new commentary Oct 30, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "COSINR" (NCT03223155), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "cosinr-03223155". If you cannot make requests, read https://www.erudio.com/reports/cosinr-nct03223155.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT03223155", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct03223155 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/cosinr-nct03223155.json
curl https://www.erudio.com/reports/cosinr-nct03223155.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "cosinr-03223155" })